Liang Yimin, Zhan Wang, Xie Yun, Wang Danru, Li Qingfeng, Zhao Grace, Chawla Smita
Shanghai Ninth People's Hospital, No. 639, Zhizaoju Road, Shanghai, 200011, People's Republic of China.
Hainan General Hospital, Qionghai City, Hainan, People's Republic of China.
Aesthetic Plast Surg. 2025 Feb 26. doi: 10.1007/s00266-024-04572-3.
Chinese individuals may seek chin enhancement to address esthetic perceptions regarding chin retrusion. Because studies of the injectable hyaluronic acid gel VYC-25L (Allergan Aesthetics, an AbbVie Company, Irvine, CA) contained few Asian subjects and none from China, its effects on chin retrusion in Chinese individuals are unclear. This 12-month, real-world evidence study evaluated the safety and effectiveness of VYC-25L for chin enhancement in Chinese adults.
At Hainan Bo'ao Super Hospital, 2 cohorts of prospectively and retrospectively enrolled adults received VYC-25L treatment (maximum 4 mL). Cohort 1 only underwent 3D imaging before and after treatment for digital analysis. The primary effectiveness measure was mean change from baseline in glabella-subnasale-pogonion (G-Sn-Pog) angle at month 3 based on 3D facial images. Both cohorts completed the Global Aesthetic Improvement Scale (GAIS; subjects and investigators) and a satisfaction questionnaire (subjects). Injection site response (ISR) and adverse events were recorded.
Of 90 subjects enrolled (cohort 1, n=36; cohort 2, n=54), 89 completed the study. Mean change from baseline in G-Sn-Pog angle at month 3 was 3.19 degrees (95% CI, 2.55-3.83; P < 0.001 vs 0), with improvement maintained through 12 months. Month 3 "improved"/"much improved" GAIS responder frequencies were 94.3% (investigators) and 97.1% (subjects); 91.5% of subjects were "satisfied"/"very satisfied" with treatment at month 3. Most (>70%) ISRs were mild or moderate in severity. Four treatment-related adverse events occurred (all mild).
VYC-25L was safe and effective for enhancement of the chin and jaw in Chinese adults.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
中国人可能会寻求隆下巴来改善对下巴后缩的审美认知。由于关于注射用透明质酸凝胶VYC - 25L(艾尔建美学公司,艾伯维公司旗下,加利福尼亚州欧文)的研究中亚洲受试者很少,且没有来自中国的受试者,因此其对中国人群下巴后缩的影响尚不清楚。这项为期12个月的真实世界证据研究评估了VYC - 25L用于中国成年人隆下巴的安全性和有效性。
在海南博鳌超级医院,2组前瞻性和回顾性纳入的成年人接受了VYC - 25L治疗(最大剂量4 mL)。第1组仅在治疗前后进行3D成像以进行数字分析。主要有效性指标是基于3D面部图像在第3个月时眉间 - 鼻下点 - 颏前点(G - Sn - Pog)角度相对于基线的平均变化。两组均完成了全球美学改善量表(GAIS;受试者和研究者)以及一份满意度问卷(受试者)。记录注射部位反应(ISR)和不良事件。
在纳入的90名受试者中(第1组,n = 36;第2组,n = 54),89名完成了研究。第3个月时G - Sn - Pog角度相对于基线的平均变化为3.19度(95% CI,2.55 - 3.83;与0相比P < 0.001),这种改善持续到12个月。第3个月时GAIS“改善”/“显著改善”的应答者频率在研究者中为94.3%,在受试者中为97.1%;91.5%的受试者在第3个月时对治疗“满意”/“非常满意”。大多数(>70%)ISR的严重程度为轻度或中度。发生了4例与治疗相关的不良事件(均为轻度)。
VYC - 25L用于中国成年人隆下巴和下颌是安全有效的。
证据水平III:本刊要求作者为每篇文章指定证据水平。有关这些循证医学评级的完整描述,请参阅目录或在线作者指南www.springer.com/00266 。